The Years Ahead in Biomedical HIV Prevention Research

Efficac	y Trial	2019	2020	2021	
Vaginal Ring Dapivirine Ring (Monthly)			Jul 2020: European Medicines Agency	Jan 2021: WHO recommends as Approved in multiple African cou	
Dapivirine Ring (Every three months)	IPM 054		issues a positive opinion		
Oral PrEP	DISCOVER	0	ct 2019: FDA approves F/TAF for adu	Ilts and adolescents who have no HIV risk fro	om re
F/TAF (Daily pill)		2016-2027: Randomized controlled tri	al of daily F/TAF in men and transgend	er women who have sex with men	
	PURPOSE 1			2021-2027: Trial of six	(-moi
Islatravir (Monthly pill)	IMPOWER-22			Randomized controlled trial of monthly i	'slatr
(Montiny pin)	IMPOWER-24			Randomized controlled trial of mont	thly i
Long-Acting Injectable Cabotegravir (Every two months)	HPTN 083	Randomized controlled trial of injectable women in Argentina, Brazil, Peru, South J		Dec	c 202
	HPTN 084	Randomized controlled trial of iniectable	le cabotegravir everv two months: on	oing in 3,200 women in Botswana, Kenya, M	olica Nalav
Lenacapavir (Every six	PURPOSE 1	······································		2021-2027: Trial of six	
months)	PURPOSE 2			2021-2027: Trial of six and gender non-binary	
🙀 🔼 Preventive HI	V Vaccine		Jan 2020: Immunizations halted ea	arly for non-efficacy	
ALVAC/gp120 w/MF59	HVTN 702	Randomized controlled trial of ALVAC/g immunizations halted for non-efficacy;		nt, six doses over 18 months; 5,400 men and	won
Ad26/gp140 boost	Imbokodo (HVTN 705/ HPX2008)	Randomized controlled trial of Ad26 pr	ime with gp140 boost; four doses ove	August 2021: The vac r 12 months; fully enrolled 2,600 women in N	
Ad26/clade C gp140 & mosaic gp140 boost	Mosaico (HVTN 706/ HPX3002)		controlled trial of Ad26 prime with cla entina, Brazil, Italy, Mexico, Peru, Pol	de C and mosaic gp140 boost; ongoing in 3,8 and, Spain, US	800
Oral PrEP and vaccine	PrEPVacc			ed controlled trial of DNA-MVA-env or DNA-en uue, South Africa, Tanzania, Uganda	v wit
Antibody VRC01	AMP (HVTN 704/ HPTN 085)	Randomized controlled trial of the VRC	01 antibody infused every two month	s; ongoing in 2,700 MSM and transgender me Jan 2021: VRC01 did not significantly reduce the c	
	AMP (HVTN 703/			risk of HIV acquisition, but it reduced risk from HIV classified as highly-sensitive to VRC01.	/ stra
	HPTN 081)	Randomized controlled trial of the VRC	01 antibody infused every two months	; ongoing in 1,900 women in Botswana, Keny	ia, M

AVAC

Status of select biomedical HIV prevention clinical trials

2022	20	2024				
additional prevention of ries and under review by						
Bioavailability tria	l of 3-monthly DVR	among 110 Women	in South A	frica		
receptive vaginal sex						
y islatravir in men and tr	women in the US ember 2022: Disconti	nued tho have sex with me				oral F/TAF.
021: FDA approves CAE ations under review wit	h other regulatory I					
onthly injectable lenacap	pavir planned in 5,0.	10 AGYW in South Ai	rica, Ugal	nda along	side daily	oral F/TAF.
nonthly injectable lenaca dividuals.	pavir in 3,000 cisge	nder MSM, transger	der wome	en, transg	ender me	n,
omen in South Africa;						
ne was safe, but did not sigr	ificantly reduce the ri	sk of HIV.				
lawi, Mozambique, Souti	h Africa, Zambia, Zi	mbabwe				
0 MSM and transgender	at preventing t	vaccine was safe, but he acquisition of HIV.	was not eff	ective		
vith F/TAF or F/TDF; plan	ned in 1668 particip	pants in	preventing study is sc	the acquis heduled to	e was not e ition of HIV conclude in the study w	and the
& women in Brazil, Peru rall rains	, Switzerland, US					
Malawi, Mozambique, T	anzania, South Afric	ca, Zimbabwe				

AVAC Advocacy. Access. Equity. April 2024